The cybercrime-as-a-service model has a new product line, with malicious large language models built without ethical ...
In interviews with Ars Technica this week, OpenAI employees revealed the extent to which the company now relies on its own AI ...
It’s happened to all of us: you find the perfect model for your needs — a bracket, a box, a cable clip, but it only comes in ...
Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback